Treatment of IBS with Diarrhea (IBS-D)

Introduction to IBS-D Treatment

The American Gastroenterological Association recommends starting with loperamide 4-12 mg daily as first-line pharmacological therapy for controlling diarrhea symptoms, then escalating to rifaximin or eluxadoline if symptoms persist after 4 weeks, reserving tricyclic antidepressants for patients with predominant abdominal pain 1, 2

Regular physical exercise is recommended to all IBS-D patients as foundational therapy that improves global symptoms, according to the American College of Gastroenterology 3, 4
Dietary counseling focusing on adequate hydration, identifying and reducing excessive intake of lactose, fructose, sorbitol, caffeine, and alcohol is advised 3
Soluble fiber (ispaghula/psyllium) should be started at 3-4 g/day, gradually increasing to avoid bloating, though evidence is stronger for IBS-C than IBS-D 3, 4
Insoluble fiber (wheat bran) should be avoided as it consistently worsens IBS-D symptoms, as suggested by the American Gastroenterological Association 4

Loperamide remains the most accessible and cost-effective first-line agent despite very low quality evidence, according to the American Gastroenterological Association 1, 2
Loperamide should be dosed at 4-12 mg daily to reduce stool frequency, urgency, and improve consistency, as recommended by the American College of Gastroenterology 5, 6, 3

Rifaximin is preferred for most patients, with a dose of 550 mg three times daily for 14 days, and patients who respond and develop recurrent symptoms can be retreated up to two times, as suggested by the American Gastroenterological Association 1, 2
Eluxadoline is best for combined pain and diarrhea, with a dose of 100 mg twice daily, and is conditionally recommended with moderate certainty evidence, according to the American Gastroenterological Association 1, 2

Tricyclic antidepressants, such as amitriptyline, are most effective for pain, with a starting dose of 10 mg once daily at bedtime, titrated by 10 mg weekly to 30-50 mg daily, as recommended by the American College of Gastroenterology 1, 2, 4
Antispasmodics, such as dicyclomine, show greater efficacy than direct smooth muscle relaxants, such as mebeverine, and are conditionally recommended with low certainty evidence, according to the American Gastroenterological Association 6, 3

Approximately 10% of IBS-D patients have bile acid malabsorption, and cholestyramine should be considered in patients with prior cholecystectomy or those with <5% retention on SeHCAT testing, as suggested by the American Gastroenterological Association 6, 3

IBS-specific cognitive behavioral therapy or gut-directed hypnotherapy should be considered when symptoms persist despite 12 months of pharmacological treatment, with moderate certainty evidence for effectiveness, according to the American Gastroenterological Association 1, 3, 4

Codeine should not be prescribed routinely due to its effectiveness and risk of sedation and drug dependency, as warned by the American Gastroenterological Association 6
IgG antibody-based food elimination diets should not be used as they lack evidence, according to the American College of Gastroenterology 4, 7
Gluten-free diets should be avoided unless celiac disease is confirmed, as recommended by the American Gastroenterological Association 4, 7
Treatment efficacy should be reviewed after 3 months and ineffective medications should be discontinued, as suggested by the American College of Gastroenterology 3, 7